In a retrospective analysis of 114 patients with advanced BRAF-mutant melanoma, the median OS was similar in those who had the anti-PD-1 in the first line and those who received BRAF ± MEK inhibitors before the anti-PD-1 (27.5 vs. 40.3 months; p = 0.71) [45]. This evidence concerns the gene MAP2K7 and melanoma.